News
ONTX
1.290
-3.73%
-0.050
Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022NEWTOWN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused o...
GlobeNewswire · 5d ago
Onconova Therapeutics appoints company's CFO Mark Guerin as the new COO
Onconova Therapeutics (NASDAQ:ONTX) appoints Mark Guerin as the COO in addition to his current role as company’s CFO. Mr. Guerin has worked in numerous roles at the company since he joined in September
Seekingalpha · 06/13 13:52
Sector Update: Health Care Stocks Fall in Early Monday Afternoon Trading
MT Newswires · 06/13 13:01
Onconova Therapeutics Gives CFO Mark Guerin Additional Role of Chief Operating Officer
MT Newswires · 06/13 10:42
53 Stocks Moving In Thursday's Mid-Day Session
Gainers
Benzinga · 06/02 16:18
BRIEF-Onconova Therapeutics Announces Abstract At The Asco Annual Meeting Highlighting Narazaciclib’S Differentiated Inhibitory And Improved Safety Profile In Preclinical Models
reuters.com · 05/26 23:54
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitorsNEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinic...
GlobeNewswire · 05/26 21:10
Is Onconova Therapeutics (NASDAQ:ONTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 05/15 12:04
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Zacks · 05/12 14:20
Onconova Q1 net loss narrows 13% although revenue remains flat
Onconova Therapuetics (NASDAQ:ONTX) saw its Q1 2022 net loss narrow ~13% year-over-year to ~4.1M (-$0.20 per share, basic and diluted) even as revenue was unchanged. Revenue in the quarter was
Seekingalpha · 05/11 21:40
Recap: Onconova Therapeutics Q1 Earnings
Onconova Therapeutics (NASDAQ:ONTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/11 21:25
BRIEF-Onconova Therapeutics Reports Q1 2022 Financial Results
reuters.com · 05/11 20:47
Onconova Therapeutics Q1 EPS $(0.20) Misses $(0.19) Estimate
Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 33.33 percent increase over losses of $(0.30) per share
Benzinga · 05/11 20:09
-- Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Posts Q1 Revenue $56,000
MT Newswires · 05/11 16:15
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Zacks · 05/11 15:20
Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:55
Onconova Therapeutics Earnings Preview
Onconova Therapeutics (NASDAQ:ONTX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Onconova Therapeutics will report an earnings per share (EP...
Benzinga · 05/10 15:07
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 22:45
Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 23:15
More
Webull provides a variety of real-time ONTX stock news. You can receive the latest news about Onconova Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib is a multi-targeted kinase inhibitor targeting cyclin-dependent kinases (CDK) 2, 4, 6, and 9, AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R). It is supporting investigator-initiated studies (ISS) that are exploring the use of rigosertib for cancers driven by mutated Ras genes, including a Phase 1/2a study of rigosertib in combination with a PD-1 inhibitor.